Janssen’s phase 3 CASSIOPEIA study of Darzalex shows increased depth of response and longer PFS in patients with newly diagnosed MM who are eligible for transplant

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the phase 3 CASSIOPEIA (MMY3006) study, an Intergroupe Francophone du Myelome (IFM) study in collaboration with the Dutch─Belgian Cooperative Trial Group.